Cancer Research · 2009 · 78 citations · 14 references
MedicineImmunologyOncologyCancer ImmunologyMetastasisTumor MicroenvironmentCancer Cell SignalingLung MetastasisMacrophage BiologyTumor Microenvironment ModulationTumor-associated MacrophagesBone Marrow - Derived CellsCancer Metastasis MechanismsCancer-associated MacrophagesMacrophage Cytokine ProductionMetastasis PromotionPhospholipase A2 PathwayTumor Microenvironment RegulationTumor-associated Macrophage Interactions
Cancer progression and metastasis involves interactions between tumor cells and the tumor microenvironment (TME). We reported that mice deficient for cytosolic phospholipase A(2) (cPLA(2)-KO) are protected against the development of lung tumors. The goal of this study was to examine the role of cPLA(2) in the TME. Mouse lung cancer cells (CMT167 and Lewis lung carcinoma cells) injected directly into lungs of syngeneic mice formed a primary tumor, and then metastasized to other lobes of the lung and to the mediastinal lymph nodes. Identical cells injected into cPLA(2)-KO mice showed a dramatic decrease in the numbers of secondary metastatic tumors. This was associated with decreased macrophage staining surrounding the tumor. Wild-type mice transplanted with cPLA(2)-KO bone marrow had a marked survival advantage after inoculation with tumor cells compared with mice receiving wild-type (WT) bone marrow. In vitro, coculturing CMT167 cells with bone marrow-derived macrophages from WT mice increased production of interleukin 6 (IL-6) by cancer cells. This increase was blocked in cocultures using cPLA(2)-KO macrophages. Correspondingly, IL-6 staining was decreased in tumors grown in cPLA(2)-KO mice. These data suggest that stromal cPLA(2) plays a critical role in tumor progression by altering tumor-macrophage interactions and cytokine production.
14
Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype
Thorsten Hagemann, Julia L. Wilson, Frances Burke et al. · The Journal of Immunology · 2006 · 408 citations
Life Sciences, Immunology, Oncology +17